BioSpace News Archive

Citryll announced the appointment of Eduardo Bravo as Chief Executive Officer.

Merck, known as MSD outside of the United States and Canada, announced that Dr. Marjorie C. Green, senior vice president and head of late-stage oncology, Global Clinical Development, is scheduled to participate in a fireside chat at the Citi 18th Annual BioPharma Conference on Wednesday, Sept. 6, 2023, at 1:50 p.m. EDT.

NRx Pharmaceuticals, Inc. announced that it entered into a definitive purchase agreement subject to standard closing conditions with accredited investors to purchase 3,000,000 shares of preferred stock at $0.40 per share, which will convert, after six months into 3,000,000 common shares and 3,000,000 warrants to purchase common stock at a purchase price of $0.40 per share; the term on these warrants is five years.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer.

Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full year ended June 30, 2023.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-15, 2023.

Reneo Pharmaceuticals, Inc. announced that the company’s management team will participate at the upcoming healthcare investor conferences.